GI, non-colorectal

Date 11 October 2016
Event ESMO 2016 Congress
Session Congress Highlights Session 2 – The best of the ESMO 2016 Congress
Topics Gastrointestinal Cancers
Presenter Arnaud Roth
Authors A.D. Roth
  • Oncosurgery, Hôpitaux Universitaires de Genève - HUG, 1211 - Geneva/CH

Login to access presentation link

Login to access webcast

ESMO 2016 presentations referenced in this Highlights

609O - Is centralization needed for esophago-gastric cancer patients with low operative risk? a nationwide study

617PD - Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Prognosis, efficacy, and safety by liver...

LBA28 - Efficacy, safety, and health-related quality of life (HRQoL) of regorafenib in patients with hepatocellular carcinoma (HCC) progressing on sorafeni... 

615O - Safety and preliminary efficacy of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (aHCC): Interim analysis of the phase...

704P - Analysis of tumor growth rate for advanced hepatocellular cancer patients receiving placebo or sorafenib in the phase 3 SHARP and Asia Pacific trials

618PD - Molecular characteristics of hepatocellular carcinomas (HCC) from different age groups

612O - Clinical next generation sequencing (NGS) of esophagogastric (EG) adenocarcinomas identifies distinct molecular signatures of response to HER2 inhibition, ...

613O - Genomic profiling of small bowel adenocarcinoma: Insights from a comparative analysis with gastric and colorectal cancer and opportunities for targ...